These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9743446)

  • 1. Targeting of human and mouse T-lymphocytes by monoclonal antibody-HPMA copolymer-doxorubicin conjugates directed against different T-cell surface antigens.
    Jelínková M; Strohalm J; Plocová D; Subr V; St'astný M; Ulbrich K; Ríhová B
    J Control Release; 1998 Mar; 52(3):253-70. PubMed ID: 9743446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab')(2)-targeted conjugates and combined therapy with immunomodulators.
    Ríhová B; Jelínková M; Strohalm J; Subr V; Plocová D; Hovorka O; Novák M; Plundrová D; Germano Y; Ulbrich K
    J Control Release; 2000 Feb; 64(1-3):241-61. PubMed ID: 10640661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene.
    Ríhová B; Jelínková M; Strohalm J; St'astný M; Hovorka O; Plocová D; Kovár M; Dráberová L; Ulbrich K
    Bioconjug Chem; 2000; 11(5):664-73. PubMed ID: 10995209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences.
    Ríhová B; Strohalm J; Hovorka O; Subr V; Etrych T; Chytil P; Pola R; Plocová D; Boucek J; Ulbrich K
    J Control Release; 2008 Apr; 127(2):110-20. PubMed ID: 18325618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
    Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
    Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate.
    Omelyanenko V; Kopecková P; Gentry C; Kopecek J
    J Control Release; 1998 Apr; 53(1-3):25-37. PubMed ID: 9741911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biorecognition of HPMA copolymer-adriamycin conjugates by lymphocytes mediated by synthetic receptor binding epitopes.
    Omelyanenko V; Kopecková P; Prakash RK; Ebert CD; Kopecek J
    Pharm Res; 1999 Jul; 16(7):1010-9. PubMed ID: 10450924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
    David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
    Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPMA copolymer-bound doxorubicin induces immunogenic tumor cell death.
    Sirova M; Kabesova M; Kovar L; Etrych T; Strohalm J; Ulbrich K; Rihova B
    Curr Med Chem; 2013; 20(38):4815-26. PubMed ID: 24083609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia.
    Kovár M; Mrkvan T; Strohalm J; Etrych T; Ulbrich K; Stastný M; Ríhová B
    J Control Release; 2003 Oct; 92(3):315-30. PubMed ID: 14568412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo effect of HPMA copolymer-bound doxorubicin targeted to transferrin receptor of B-cell lymphoma 38C13.
    Kovár M; Strohalm J; Ulbrich K; Ríhová B
    J Drug Target; 2002 Feb; 10(1):23-30. PubMed ID: 11996083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding and cytotoxicity of HPMA copolymer conjugates to lymphocytes mediated by receptor-binding epitopes.
    Tang A; Kopeiková P; Kopeckevá J
    Pharm Res; 2003 Mar; 20(3):360-7. PubMed ID: 12669954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Participation of L3T4 in T cell activation in the absence of class II major histocompatibility complex antigens. Inhibition by anti-L3T4 antibodies is a function both of epitope density and mode of presentation of anti-receptor antibody.
    Owens T; Fazekas de St Groth B
    J Immunol; 1987 Apr; 138(8):2402-9. PubMed ID: 2435798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin attached to HPMA copolymer via amide bond modifies the glycosylation pattern of EL4 cells.
    Kovar L; Etrych T; Kabesova M; Subr V; Vetvicka D; Hovorka O; Strohalm J; Sklenar J; Chytil P; Ulbrich K; Rihova B
    Tumour Biol; 2010 Aug; 31(4):233-42. PubMed ID: 20556593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Starlike vs. classic macromolecular prodrugs: two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs.
    Jelínková M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
    Pharm Res; 2003 Oct; 20(10):1558-64. PubMed ID: 14620507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
    Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
    J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPMA-based biodegradable hydrogels containing different forms of doxorubicin. Antitumor effects and biocompatibility.
    Ríhová B; Srogl J; Jelínková M; Hovorka O; Buresová M; Subr V; Ulbrich K
    Ann N Y Acad Sci; 1997 Dec; 831():57-71. PubMed ID: 9616702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective activation of resting mouse T lymphocytes by cross-linking submitogenic concentrations of the T cell antigen receptor with either Lyt-2 or L3T4.
    Eichmann K; Jönsson JI; Falk I; Emmrich F
    Eur J Immunol; 1987 May; 17(5):643-50. PubMed ID: 3108015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties.
    Etrych T; Jelínková M; Ríhová B; Ulbrich K
    J Control Release; 2001 May; 73(1):89-102. PubMed ID: 11337062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
    Etrych T; Mrkvan T; Ríhová B; Ulbrich K
    J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.